Hot on the heels of yesterday’s news that Revance Therapeutics is moving forward with trials of a product currently called DAXI, medical aesthetic company Evolus Inc has announced that the European Commission (EC) has approved the marketing of Nuceiva prabotulinumtoxinA (branded Jeuveau in the US and known in other markets as Nabota).
The marketing has been approved for the temporary improvement in the appearance of moderate to severe glabellar lines. The EC decision still applies in the UK.
It will mean more choice and more competition on price when the product enters the market in big numbers – despite only being approved for the glabella currently.
The global POM for anti-wrinkle market is estimated at $4.3bn in 2018, and is projected to be worth a staggering $9bn by 2027. This continued growth is why companies are battling to get a share of this massive market.